Cited by 292

The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.

A snapshot of the PD-1/PD-L1 pathway

Open access

Ghosh, Chinmoy, Luong, Gary, Sun, Yue·2021·Journal of Cancer

Open this paper in CoChat — free account

Abstract

Cancer cells can evade the attack from host immune systems via hijacking the regulatory circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by blockade of immune checkpoints is considered as a promising strategy to treat cancer. Programmed death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) are critical immune checkpoint proteins that responsible for negative regulation of the stability and the integrity of T-cell immune function. Anti-PD-1/PD-L1 drugs have been developed for immune checkpoint blockade and can induce clinical responses across different types of cancers, which provides a new hope to cure cancer. However, the patients' response rates to current anti-PD-1 or anti-PD-L1 therapies are still low and many initial responders finally develop resistance to these therapies. In this review, we provides a snapshot of the PD-1/PD-L1 molecular structure, mechanisms controlling their expression, signaling modulated by PD-1/PD-L1, current anti-PD-1/PD-L1 therapies, and the future perspectives to overcome the resistance.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.7150/jca.57334

Cites

155 of 155 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“From a recent phase I clinical trial, data indicated the administration of anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab), in patients with metastatic melanoma resulted in similar response rates in the setting of concurrent therapy regardless of PD-L1 expression in pretreatment tumor tissues [118].”
Background
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
Stimpfel, M., & Virant-Klun, I. (2016) · Journal of Cancer Stem Cell Research · doi:10.14343/jcscr.2016.4e1003 · Cited by 2,540
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360 · cited 2×
“CTLA-4 functions at the early stage of T-cell immune response primarily in lymph nodes, whereas PD-1 functions at the later stage of T-cell immune response primarily in peripheral tissues [24].”
Background
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“The CTLA-4-B7-1/B7-2 binding mediates coinhibitory signal to prevent T-cell activation [21].”
Background
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
A Theory of Self-Nonself Discrimination: Paralysis and induction involve the recognition of one and two determinants on an antigen, respectively.
Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,692
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685 · cited 1×
“This finding came as a surprise, because B7-1 was previously believed to only act as a functional ligand for CD28 and CTLA-4 [35, 36].”
Background
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677 · cited 1×
“stimulation of antigen presentation in IFN-γ can also downregulate the activation of T-cells by inducing PD-L1 expression [75, 76].”
Background
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
The molecular landscape of head and neck cancer
Leemans, C. R., Snijders, P. J. F., & Brakenhoff, R. H. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.11 · Cited by 1,395
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,231
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation
Salomon, B., & Bluestone, J. A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.225 · Cited by 1,006
CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy
Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 998
The multidimensional mechanisms of long noncoding RNA function
Marchese, F. P., Raimondi, I., & Huarte, M. (2017) · Genome Biology · doi:10.1186/s13059-017-1348-2 · Cited by 975
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1259-z · Cited by 970
TIM3 comes of age as an inhibitory receptor
Wolf, Y., Anderson, A. C., & Kuchroo, V. K. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0224-6 · Cited by 959
LAG 3 (CD 223) as a cancer immunotherapy target
Andrews, L. P., Marciscano, A. E., Drake, C. G., & Vignali, D. A. A. (2017) · Immunological Reviews · doi:10.1111/imr.12519 · Cited by 956
REGULATION OF IMMUNE RESPONSES THROUGH INHIBITORY RECEPTORS
Long, E. O. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.875 · Cited by 939
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
LAG-3, a novel lymphocyte activation gene closely related to CD4.
Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., & Hercend, T. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.5.1393 · Cited by 925
B70 antigen is a second ligand for CTLA-4 and CD28
Azuma, M., Ito, D., Yagita, H., Okumura, K., Phillips, J. H., Lanier, L. L., & Somoza, C. (1993) · Nature · doi:10.1038/366076a0 · Cited by 909
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
Kuang, D.-M., Zhao, Q., Peng, C., Xu, J., Zhang, J.-P., Wu, C., & Zheng, L. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 903
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486598 · Cited by 848
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 804
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778 · cited 2×
“The effects of PD-1-inhibited ERK activation was found to be nullified through IL-2, IL-7, or IL-15 activation [63].”
Background
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776
Enhancing SIV-specific immunity in vivo by PD-1 blockade
Velu, V., Titanji, K., Zhu, B., Husain, S., Pladevega, A., Lai, L., Vanderford, T. H., Chennareddi, L., Silvestri, G., Freeman, G. J., et al. (2009) · Nature · doi:10.1038/nature07662 · Cited by 771
Partners in transcription: NFAT and AP-1
Macián, F., López-Rodríguez, C., & Rao, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204386 · Cited by 766
Programmed death ligand-1 expression in non-small cell lung cancer
Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V. K., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 755
T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.
Linsley, P. S., Clark, E. A., & Ledbetter, J. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5031 · Cited by 747
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.-F., Gondek, D., Wang, Y., Fava, R. A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 710
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells
Latchman, Y. E., Liang, S. C., Wu, Y., Chernova, T., Sobel, R. A., Klemm, M., Kuchroo, V. K., Freeman, G. J., & Sharpe, A. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307252101 · Cited by 636
The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors
Ghebeh, H., Mohammed, S., Al-Omair, A., Qattant, A., Lehe, C., Al-Qudaihi, G., Elkum, N., Alshabanah, M., Bin Amer, S., Tulbah, A., et al. (2006) · Neoplasia · doi:10.1593/neo.05733 · Cited by 612
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Azuma, T., Yao, S., Zhu, G., Flies, A. S., Flies, S. J., & Chen, L. (2008) · Blood · doi:10.1182/blood-2007-11-123141 · Cited by 531
Application of PD-1 Blockade in Cancer Immunotherapy
Wu, X., Gu, Z., Chen, Y., Chen, B., Chen, W., Weng, L., & Liu, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.006 · Cited by 531
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X.-G., & Xu, N. (2006) · Acta Histochemica · doi:10.1016/j.acthis.2006.01.003 · Cited by 495
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., et al. (2015) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 495
Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Niu, G., & Chen, X. (2010) · Current Drug Targets · doi:10.2174/138945010791591395 · Cited by 451
NFATc1 Regulates PD-1 Expression upon T Cell Activation
Oestreich, K. J., Yoon, H., Ahmed, R., & Boss, J. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4832 · Cited by 416
Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Chen, L., Zhang, Z.-Y., Edidin, M. A., Nathenson, S. G., & Almo, S. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00051-2 · Cited by 410
Oncolytic Viruses and Their Application to Cancer Immunotherapy
Chiocca, E. A., & Rabkin, S. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0015 · Cited by 408
Direct Regulation of ZAP-70 by SHP-1 in T Cell Antigen Receptor Signaling
Plas, D. R., Johnson, R., Pingel, J. T., Matthews, R. J., Dalton, M., Roy, G., Chan, A. C., & Thomas, M. L. (1996) · Science · doi:10.1126/science.272.5265.1173 · Cited by 390
The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., & Chen, H. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.180 · Cited by 386
A two-step, two-signal model for the primary activation of precursor helper T cells
Bretscher, P. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.185 · Cited by 386
618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2005) · Journal of Urology · doi:10.1016/s0022-5347(18)34858-4 · Cited by 386
IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0993 · Cited by 376
Absence of B7-dependent responses in CD28-deficient mice
Green, J. M., Noel, P. J., Sperling, A. I., Walunas, T. L., Gray, G. S., Bluestone, J. A., & Thompson, C. B. (1994) · Immunity · doi:10.1016/1074-7613(94)90092-2 · Cited by 376
CTLA-4: a negative regulator of autoimmune disease.
Karandikar, N. J., Vanderlugt, C. L., Walunas, T. L., Miller, S. D., & Bluestone, J. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.783 · Cited by 376
B7-H1 Determines Accumulation and Deletion of Intrahepatic CD8+ T Lymphocytes
Dong, H., Zhu, G., Tamada, K., Flies, D. B., van Deursen, J. M. A., & Chen, L. (2004) · Immunity · doi:10.1016/s1074-7613(04)00050-0 · Cited by 372
Talimogene laherparepvec: First in class oncolytic virotherapy
Conry, R. M., Westbrook, B., McKee, S., & Norwood, T. G. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1412896 · Cited by 335
The B7 family of immune-regulatory ligands.
Collins, M. A., Ling, V., & Carreno, B. M. (2005) · Genome biology · doi:10.1186/gb-2005-6-6-223 · Cited by 332
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
Park, J.-J., Omiya, R., Matsumura, Y., Sakoda, Y., Kuramasu, A., Augustine, M. M., Yao, S., Tsushima, F., Narazaki, H., Anand, S., et al. (2010) · Blood · doi:10.1182/blood-2010-01-265975 · Cited by 330
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Tang, C., Wang, X., Soh, H., Seyedin, S., Cortez, M. A., Krishnan, S., Massarelli, E., Hong, D., Naing, A., Diab, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0069 · Cited by 322
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
Xiao, Y., Yu, S., Zhu, B., Bedoret, D., Bu, X., Francisco, L. M., Hua, P., Duke-Cohan, J. S., Umetsu, D. T., Sharpe, A. H., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130790 · Cited by 321
T cell anergy and costimulation
Appleman, L. J., & Boussiotis, V. A. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00009.x · Cited by 305
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination
Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40070 · Cited by 295
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Zerdes, I., Matikas, A., Bergh, J., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 292
Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction
Wang, S., Bajorath, J., Flies, D. B., Dong, H., Honjo, T., & Chen, L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021752 · Cited by 291
Costimulatory and coinhibitory receptors in anti‐tumor immunity
Driessens, G., Kline, J., & Gajewski, T. F. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00771.x · Cited by 286
Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses
Bennett, F., Luxenberg, D., Ling, V., Wang, I.-M., Marquette, K., Lowe, D., Khan, N., Veldman, G., Jacobs, K. A., Valge-Archer, V. E., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.711 · Cited by 281
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Engeland, C. E., Grossardt, C., Veinalde, R., Bossow, S., Lutz, D., Kaufmann, J. K., Shevchenko, I., Umansky, V., Nettelbeck, D. M., Weichert, W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.160 · Cited by 280
B7-H1 (Programmed Death-1 Ligand) on Dendritic Cells Is Involved in the Induction and Maintenance of T Cell Anergy
Selenko-Gebauer, N., Majdic, O., Szekeres, A., Höfler, G., Guthann, E., Korthäuer, U., Zlabinger, G., Steinberger, P., Pickl, W. F., Stockinger, H., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3637 · Cited by 263
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
Fujita, Y., Yagishita, S., Hagiwara, K., Yoshioka, Y., Kosaka, N., Takeshita, F., Fujiwara, T., Tsuta, K., Nokihara, H., Tamura, T., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.10 · Cited by 261
The dual-function CD150 receptor subfamily: the viral attraction
Sidorenko, S. P., & Clark, E. A. (2003) · Nature Immunology · doi:10.1038/ni0103-19 · Cited by 252
T‐cell tolerance or function is determined by combinatorial costimulatory signals
Nurieva, R., Thomas, S., Nguyen, T., Martin‐Orozco, N., Wang, Y., Kaja, M., Yu, X., & Dong, C. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601146 · Cited by 245
Genetic and Epigenetic Regulation of PD-1 Expression
Bally, A. P. R., Austin, J. W., & Boss, J. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502643 · Cited by 243
Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR‐138 targets TERT and PD‐L1
Zhang, X., Xu, L., & Wang, F. (2017) · Cell Biology International · doi:10.1002/cbin.10826 · Cited by 241
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy
Tsushima, F., Yao, S., Shin, T., Flies, A., Flies, S., Xu, H., Tamada, K., Pardoll, D. M., & Chen, L. (2007) · Blood · doi:10.1182/blood-2006-11-060087 · Cited by 239
CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis
Perrin, P. J., Maldonado, J. H., Davis, T. A., June, C. H., & Racke, M. K. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.4.1333 · Cited by 226
CTLA-4 and T cell activation
Oosterwegel, M. A., Greenwald, R. J., Mandelbrot, D. A., Lorsbach, R. B., & Sharpe, A. H. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)80047-8 · Cited by 208
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
Lázár-Molnár, E., Yan, Q., Cao, E., Ramagopal, U., Nathenson, S. G., & Almo, S. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804453105 · Cited by 206
Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma
Johnson, D. B., Puzanov, I., & Kelley, M. C. (2015) · Immunotherapy · doi:10.2217/imt.15.35 · Cited by 203
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
Kudo, M. (2020) · Cancers · doi:10.3390/cancers12051089 · Cited by 197
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
Li, Y.-L., Li, Y.-L., Zhao, H., Ren, X.-B., Zhao, H., & Ren, X.-B. (2016) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2015.0070 · Cited by 196
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
Chowdhury, P. S., Chamoto, K., & Honjo, T. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12708 · Cited by 191
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells
Goldberg, M. V., Maris, C. H., Hipkiss, E. L., Flies, A. S., Zhen, L., Tuder, R. M., Grosso, J. F., Harris, T. J., Getnet, D., Whartenby, K. A., et al. (2007) · Blood · doi:10.1182/blood-2006-12-062422 · Cited by 187
Regulation of Cell Surface Expression of CTLA-4 by Secretion of CTLA-4-Containing Lysosomes Upon Activation of CD4+ T Cells
Iida, T., Ohno, H., Nakaseko, C., Sakuma, M., Takeda-Ezaki, M., Arase, H., Kominami, E., Fujisawa, T., & Saito, T. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.5062 · Cited by 173
MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer
Zhu, J., Chen, L., Zou, L., Yang, P., Wu, R., Mao, Y., Zhou, H., Li, R., Wang, K., Wang, W., et al. (2014) · Human Immunology · doi:10.1016/j.humimm.2014.01.006 · Cited by 171
Interaction of SHP‐2 SH2 domains with PD‐1 ITSM induces PD‐1 dimerization and SHP‐2 activation
Patsoukis, N., Duke-Cohan, J. S., Chaudhri, A., Aksoylar, H.-I., Wang, Q., Council, A., Berg, A., Freeman, G. J., & Boussiotis, V. A. (2020) · Communications Biology · doi:10.1038/s42003-020-0845-0 · Cited by 169
Lack of SHPTP1 results in src-family kinase hyperactivation and thymocyte hyperresponsiveness.
Lorenz, U., Ravichandran, K. S., Burakoff, S. J., & Neel, B. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9624 · Cited by 169
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
Dang, T. O., Ogunniyi, A., Barbee, M. S., & Drilon, A. E. D. C. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1123626 · Cited by 162
Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo
Rota, G., Niogret, C., Dang, A. T., Barros, C. R., Fonta, N. P., Alfei, F., Morgado, L., Zehn, D., Birchmeier, W., Vivier, E., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.026 · Cited by 155
Constitutive and Inducible Expression of B7 Family of Ligands by Human Airway Epithelial Cells
Kim, J., Myers, A. C., Chen, L., Pardoll, D. M., Truong-Tran, Q. A., Lane, A. P., McDyer, J. F., Fortuno, L. V., & Schleimer, R. P. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0129oc · Cited by 143
Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
Pelster, M. S., & Amaria, R. N. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919830826 · Cited by 142
PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
Xu, X., Hou, B., Fulzele, A., Masubuchi, T., Zhao, Y., Wu, Z., Hu, Y., Jiang, Y., Ma, Y., Wang, H., et al. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.201905085 · Cited by 138
miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy
Xi, J., Huang, Q., Wang, L., Ma, X., Deng, Q., Kumar, M., Zhou, Z., Li, L., Zeng, Z., Young, K. H., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0178-3 · Cited by 137
Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1
Xiao, G., Deng, A., Liu, H., Ge, G., & Liu, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206370109 · Cited by 133
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8[+] T lymphocytes are prognostic factors of human ovarian cancer
濱西, 潤. (2009) · Kyoto University Research Information Repository (Kyoto University) · Cited by 131
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.
Flies, D. B., Sandler, B. J., Sznol, M., & Chen, L. (2011) · PubMed Central · Cited by 123
Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma
Tang, Y., He, Y., Shi, L., Yang, L., Wang, J., Lian, Y., Fan, C., Zhang, P., Guo, C. J., Zhang, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16545 · Cited by 121
New monoclonal antibodies against B-cell antigens: Possible new strategies for diagnosis of primary cutaneous B-cell lymphomas
Fanoni, D., Tavecchio, S., Recalcati, S., Balice, Y., Venegoni, L., Fiorani, R., CROSTI, C., & Berti, E. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.09.022 · Cited by 115
The use of immunotherapy in the treatment of melanoma
Achkar, T., & Tarhini, A. A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0458-3 · Cited by 110
B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer
Liu, Y., Zeng, B., Zhang, Z., Zhang, Y. C., & Yang, R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.030 · Cited by 105
A frequent somatic mutation in CD274 3′-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding
Wang, W., Sun, J., Li, F., Li, R. Q., Gu, Y., Liu, C., Peng, Y., Zhu, M., Chen, L., Tian, W., et al. (2011) · Human Mutation · doi:10.1002/humu.22014 · Cited by 95
Conditional Deletion of Shp2 Tyrosine Phosphatase in Thymocytes Suppresses Both Pre-TCR and TCR Signals
Nguyen, T. V., Ke, Y., Zhang, E. E., & Feng, G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.5990 · Cited by 93
Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model
Wu, L., Wu, M. O., de la Maza, L. M., Yun, Z., Yu, J. L., Zhao, Y. D., Cho, J., & de Perrot, M. E. (2015) · Oncotarget · doi:10.18632/oncotarget.3487 · Cited by 87
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Hamanishi, J. (2009) · Kyoto University Research Information Repository (Kyoto University) · Cited by 84
Targeting Mutant BRAF in Melanoma: Current Status and Future Development of Combination Therapy Strategies
Kudchadkar, R. R., Paraiso, K. H. T., & Smalley, K. S. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824b436e · Cited by 80
The miR‐3127‐5p/p‐ STAT 3 axis up‐regulates PD ‐L1 inducing chemoresistance in non‐small‐cell lung cancer
Tang, D., Zhao, D., Wu, Y., Yao, R., Zhou, L., Lu, L., Gao, W., & Sun, Y. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13657 · Cited by 80
Self-citation
The combination of checkpoint immunotherapy and targeted therapy in cancer
Karachaliou, N., Gonzalez-Cao, M., Sosa, A. E., Berenguer, J., Bracht, J. W. P., Ito, M., & Rosell, R. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.47 · Cited by 71
Upregulation of long noncoding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM‐JAK‐PD‐L1 pathway
Zhang, C., Jiang, F., Su, C., Xie, P., & Xu, L. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28444 · Cited by 63
Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease
Karandikar, N. J., Vanderlugt, C. L., Bluestone, J. A., & Miller, S. D. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00058-7 · Cited by 55
PD-1 deficiency reveals various tissue-specific autoimmunity by H-2 b and dose-dependent requirement of H-2 g7 for diabetes in NOD mice
Yoshida, T., Jiang, F., Honjo, T., & Okazaki, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710951105 · Cited by 51
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer
Langer, C. J., Socinski, M. A., Patel, J. D., Sandler, A. B., Schiller, J. H., Leon, L., Hazard, S. J., & Ramalingam, S. S. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000163 · Cited by 50
A broad-spectrum integrative design for cancer prevention and therapy: The challenge ahead
Bishayee, A., & Block, K. I. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.002 · Cited by 50
Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Lorenz, M. C., Cammer, M., Chen, L., Zhang, Z., Edidin, M. A., et al. (2004) · Immunity · doi:10.1016/s1074-7613(04)00114-1 · Cited by 46
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Yokosuka, T., Takamatsu, M., Kobayashi, W., Hashimoto, A. S., Azuma, M., & Saito, T. (2012) · The Journal of Cell Biology · doi:10.1083/jcb1976oia8 · Cited by 36
Regulation of the Induction and Function of Cytotoxic T Lymphocytes by Natural Killer T Cell
Ito, H., & Seishima, M. (2010) · BioMed Research International · doi:10.1155/2010/641757 · Cited by 32
Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs
Lei, D., Lu, S., & Li, Y. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00735-9 · Cited by 30
Therapeutic Blockade of T- Cell Antigen Receptor Signal Transduction and Costimulation in Autoimmune Disease
Podojil, J. R., Turley, D. M., & Miller, S. D. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-09789-3_18 · Cited by 15
Improved transplantation outcome by epigenetic changes
Schildberg, F. A., Hagmann, C. A., Böhnert, V., & Tolba, R. H. (2010) · Transplant Immunology · doi:10.1016/j.trim.2010.05.001 · Cited by 14
Pembrolizumab in the Management of Metastatic Melanoma
Spain, L. A., Younger, E., Hatipoglu, E., & Larkin, J. (2015) · Melanoma Management · doi:10.2217/mmt.15.33 · Cited by 8

Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Parvez, A., Choudhary, F., Mudgal, P., Khan, R., Qureshi, K. A., Farooqi, H., & Aspatwar, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296341 · Cited by 216
The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2
Chaib, S., López-Domínguez, J. A., Lalinde-Gutiérrez, M., Prats, N., Marin, I., Boix, O., García-Garijo, A., Meyer, K., Muñoz, M. I., Aguilera, M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00712-x · Cited by 114

See all 292

Authors: Ghosh, C., Luong, G., & Sun, Y.
Venue: Journal of Cancer
Publisher: Ivyspring International Publisher
Published: 2021
Volume: 12
Issue: 9
Pages: 2735-2746
ISSN: 1837-9664 (ISSN-L)
DOI: 10.7150/jca.57334
OpenAlex: W3136328381
Cited by: 292
References: 155
FWCI: 14.92
Type: journal article
Language: en
Open access: gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

A snapshot of the PD-1/PD-L1 pathway

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources